All In Biotech

Drug Trial Radar · NCT03969329

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 20, 2019

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in pediatric participants between ≥ 2 to \< 18 years of age, with chronic kidney disease (CKD) on hemodialysis.

Conditions

  • Secondary Hyperparathyroidism

Interventions

  • EtelcalcetideDrug

    Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling iPTH, calcium (Ca), and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in iPTH at Weeks 20 to 26Time frame: Baseline, Week 20 to 26

Locations

23 sites in 12 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Terminated

  • Fakultni nemocnice v Motole

    Prague, Czechia · Completed

  • Hospices Civils de Lyon Hopital Femme Mere Enfant

    Bron, France · Terminated

  • Hopital Armand Trousseau

    Paris, France · Completed

  • Kindernierenzentrum Bonn

    Bonn, Germany · Completed

  • Universitaetsklinikum Koeln

    Cologne, Germany · Recruiting

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, Germany · Completed

  • Medizinische Hochschule Hannover

    Hanover, Germany · Completed

  • Universitaetsklinikum Heidelberg, Zentrum fuer Kinder und Jugendmedizin

    Heidelberg, Germany · Recruiting

  • General Children Hospital Panagioti and Aglaias Kyriakou

    Athens, Greece · Recruiting

  • Ippokrateio General Hospital of Thessaloniki

    Thessaloniki, Greece · Recruiting

  • Semmelweis Egyetem

    Budapest, Hungary · Terminated

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar

    Szeged, Hungary · Terminated

  • Azienda Ospedaliera Universitaria Meyer

    Florence, Italy · Terminated

  • Childrens Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos

    Vilinus, Lithuania · Terminated

  • Uniwersytecki Szpital Dzieciecy w Krakowie

    Krakow, Poland · Terminated

  • Unidade Local de Saude de Santo Antonio, EPE - Hospital de Santo Antonio

    Porto, Portugal · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Andalusia, Spain · Terminated

  • Hospital Universitari Vall d Hebron

    Barcelona, Catalonia, Spain · Recruiting

  • Royal Hospital for Sick Children

    Glasgow, United Kingdom · Recruiting

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom · Recruiting

  • Great Ormond Street Hospital for Children

    London, United Kingdom · Terminated

  • University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.